GuidelineAnnals of the rheumatic diseases2010
Treating rheumatoid arthritis to target: recommendations of an international task force.
Guideline in Annals of the rheumatic diseases, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 5 registered trials, which are not on this map. Cited by 758 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparison of the Efficacy and Safety of Two Different Starting Dosages of Prednisolone in Early Active Rheumatoid Arthritis: a Randomized, Placebo Controlled Trial
Treat-to-target in RA: Collaboration To Improve adOption and adhereNce (TRACTION)
Assessment of Tender & Swollen Joints Count Score Performed by a Rheumatologist And Rheumatology Nurses in Patients With Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA)
Self-management Nursing Intervention for Women With Rheumatoid Arthritis: A Pragmatic Randomized Clinical Trial
Ultrasonographic Evaluation of Asymptomatic Shoulder Joint Pathologies in Rheumatoid Arthritis Patients Compared to Healthy Controls: Case-Controlled Study
Who cites it
758 citing papers in PubMed, 6 syntheses or guidelines pooled it, 2,076 citations in OpenAlex.
- Therapeutic approaches for difficult-to-treat rheumatoid arthritis: a systematic literature review of current evidence.RMD open · 2026Pooled it
- Barriers to, Facilitators of, and Interventions to Support Treat-to-Target Implementation in Rheumatoid Arthritis: A Systematic Review.Arthritis care & research · 2024Pooled it
- Remission definitions guiding immunosuppressive therapy in rheumatoid arthritis: which is best fitted for the purpose?RMD open · 2024Pooled it
- Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica.Annals of the rheumatic diseases · 2024Pooled it
- Placebo-Related Adverse Events in Rheumatoid Arthritis.Biomolecules · 2022Pooled it
- The EANM guideline for radiosynoviorthesis.European journal of nuclear medicine and molecular imaging · 2022Guideline
- The effects of intermittent fasting on antioxidant and inflammatory markers and liver enzymes in postmenopausal, overweight and obese women with rheumatoid arthritis: a randomized controlled trial.Scientific reports · 2025Trial
- The Structured Delegation of Medical Care Services for Patients With Inflammatory Rheumatic Diseases.Deutsches Arzteblatt international · 2022Trial
- Validity and risk of adopting PGA ≤ 2 as a remission criteria of Boolean in clinical practice in patient with rheumatoid arthritis.Scientific reports · 2022Trial
- Artificial intelligence in biomarker discovery for diseases: diagnostic and therapeutic prospects.Signal transduction and targeted therapy · 2026Review
- Article
- Adherence to treat-to-target recommendations in juvenile idiopathic arthritis in clinical practice.Pediatric rheumatology online journal · 2026Observational
- Beyond Disease Activity: Fatigue and Health-Related Quality of Life in Rheumatoid Arthritis Remission and Low Disease Activity.Journal of clinical medicine · 2026Article
- Atlantoaxial Dislocation: Myths, Evidence, and a Practical Clinical Framework.International journal of rheumatic diseases · 2026Article
- An Open-Label, Comparative, Parallel Clinical Trial of the Safety, Pharmacokinetics and Immunogenicity of the Ustekinumab Biosimilar GNR-068 and the Originally Developed Ustekinumab as a Reference Drug After a Single Subcutaneous Administration in Healthy Male Volunteers.Antibodies (Basel, Switzerland) · 2026Article
- Adopting treat-to-target in paediatric rheumatic diseases.Nature reviews. Rheumatology · 2026Article
- CAR T cell therapy beyond cancer: current status, challenges and future prospects.Signal transduction and targeted therapy · 2026Review
- Reproducibility and Potential for Input Reduction for Torque Teno Virus DNA Quantification in Rheumatoid Arthritis.Medical sciences (Basel, Switzerland) · 2026Article
- Achieving Canadian Treat-to-Target Criteria in Moderate-to-Severe Atopic Dermatitis: A Retrospective Analysis of Outcomes from Real-World Canadian Practice.Dermatology and therapy · 2026Article
- Is the temporomandibular joint affected by rheumatoid arthritis? A comparative investigation with knee arthritis in an experimental rat model.Journal of anatomy · 2026Article
698 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
- Erratum issuedvan der Heijde, Desirée [corrected to van der Heijde, Désirée]
Authors and funding
24 authors at 19 institutions in 12 countries.
Funding
Abstract
backgroundAiming at therapeutic targets has reduced the risk of organ failure in many diseases such as diabetes or hypertension. Such targets have not been defined for rheumatoid arthritis (RA).
objective/st> To develop recommendations for achieving optimal therapeutic outcomes in RA.
methodsA task force of rheumatologists and a patient developed a set of recommendations on the basis of evidence derived from a systematic literature review and expert opinion; these were subsequently discussed, amended and voted upon by >60 experts from various regions of the world in a Delphi-like procedure. Levels of evidence, strength of recommendations and levels of agreement were derived.
resultsThe treat-to-target activity resulted in 10 recommendations. The treatment aim was defined as remission with low disease activity being an alternative goal in patients with long-standing disease. Regular follow-up (every 1-3 months during active disease) with appropriate therapeutic adaptation to reach the desired state within 3 to a maximum of 6 months was recommended. Follow-up examinations ought to employ composite measures of disease activity which include joint counts. Additional items provide further details for particular aspects of the disease. Levels of agreement were very high for many of these recommendations (> or =9/10).
conclusionThe 10 recommendations are supposed to inform patients, rheumatologists and other stakeholders about strategies to reach optimal outcomes of RA based on evidence and expert opinion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.